10/15/2015 | PP | Keryx will conduct $125 million private placement of convertible notes
|
5/4/2011 | PP | Keryx Biopharmaceuticals prices $33 million public offering of stock
|
9/25/2009 | PP | New Issue: Keryx Biopharmaceuticals to raise $20 million in registered direct sale
|
11/13/2006 | BT | Keryx on track to complete enrollment in pivotal phase 3 trial by year end
|
11/2/2006 | BT | Keryx keeps buy rating from Merrill
|
11/2/2006 | BT | Jefferies keeps Keryx at buy, $25 price target
|
11/1/2006 | BT | Keryx ends third quarter with more than $140 million in cash and equivalents
|
10/4/2006 | BT | Keryx reiterated at buy by Jefferies
|
9/29/2006 | BT | Merrill reiterates Keryx at buy
|
9/29/2006 | BT | Keryx reiterated at buy by Jefferies
|
8/17/2006 | BT | Jefferies reiterates Keryx at buy
|
8/10/2006 | BT | Keryx reiterated at buy by Jefferies
|
8/9/2006 | BT | Merrill reiterates Keryx at buy
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
6/30/2006 | BT | Keryx rated at buy by Jefferies
|
6/29/2006 | BT | Keryx says Zerenex found safe across all treatment doses
|
6/29/2006 | BT | Keryx maintained at buy by Merrill
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
6/27/2006 | BT | Keryx says it will complete enrollment in phase 3 Sulonex trial in second half of the year
|
6/6/2006 | BT | Keryx announces positive data of KRX-0401 in cancer; phase 2 and 3 trials planned
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
6/1/2006 | BT | Merrill Lynch comments on DPP-IV
|
5/8/2006 | BT | Merrill puts Keryx at buy
|
5/8/2006 | BT | Keryx at buy by Jefferies
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
3/28/2006 | PP | Market Commentary: Sequenom's stock drops 9% after $30 million PIPE, earnings report; Calibre raises $6.32 million
|
3/27/2006 | BT | Market Commentary: Amylin drops 3% on follow-on; Keryx up 3% on PIPE; Cubist off; Cephalon off, Generex dives 20%
|
3/27/2006 | PP | Market Commentary: Keryx Biopharmaceuticals stock rises on $82.8 million direct deal; Metabasis to raise $39.96 million
|
3/27/2006 | BTPP | New Issue: Keryx Biopharmaceuticals secures $82.8 million from direct placement of stock
|
3/23/2006 | BT | Keryx acquires Accumin diagnostic for detection of precursor to diabetic kidney disease
|
3/2/2006 | BT | Keryx starts phase 2 study of KRX-0401 for the treatment of refractory leukemia
|
3/2/2006 | BT | Keryx keeps buy rating from Jefferies
|
3/2/2006 | BT | Merrill maintains Keryx at buy
|
2/16/2006 | BT | Merrill gives Keryx buy rating
|
2/15/2006 | BT | Keryx Biopharmaceuticals announces in-licensing of Zerenex, expansion of renal franchise
|
2/15/2006 | BT | Jefferies puts Keryx at buy
|
1/3/2006 | BT | Keryx starts clinical studies of KRX-0401 in patients with multiple myeloma
|
1/3/2006 | BT | Jefferies rates Keryx a buy
|
12/30/2005 | BT | Keryx Biopharmaceuticals files $150 million stock shelf
|
12/8/2005 | BT | Keryx says preclinical studies demonstrate effectiveness of KRX-0401 against multiple myeloma cells
|
11/18/2005 | BT | Merrill reiterates Keryx at buy
|
11/14/2005 | BT | Market Commentary: OSI, Eyetech tie knot; Genentech hits new high; SkyePharma soars on buyout interest; Onyx launches
|
11/14/2005 | BT | Merrill Lynch maintains Keryx at buy
|
11/14/2005 | BT | Jefferies maintains Keryx at buy
|
11/11/2005 | BT | Keryx reports positive phase 2 trial results for KRX-101 for treatment of diabetic nephropathy
|
11/7/2005 | BT | Merrill Lynch maintains Keryx at buy
|
11/4/2005 | BT | Jefferies maintains Keryx's buy rating
|
10/4/2005 | BT | Market Commentary: CancerVax crashes; Serono slips; Protein Design Labs cheered; Celgene off; Keryx up
|
10/3/2005 | BT | Keryx initiated by Merrill Lynch at buy
|
8/3/2005 | BT | Keryx maintained by Jefferies at buy
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/18/2005 | BT | Keryx Biopharmaceuticals greenshoe exercised in full, lifting stock offer to $81.2 million
|
7/15/2005 | BT | New Issue: Keryx $70.7 million secondary shares priced at $14.05, pat with Thursday's close
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
7/11/2005 | BT | Keryx Biopharmaceuticals plans 5 million share follow-on offering
|
7/11/2005 | BT | Market Commentary: Accentia runs into resistance; Canadian biotechs tap PIPEs; eyes on Genentech; Mylan up
|